Khyati Niral Shah
Research Subjects
Khyati Niral Shah has a total of 111 co-authors. Here are the top co-authors by number of shared publications:
- Alessandra di Pietro
Pfizer 18 , Milan, Italy
8 shared publications - Ana Arance
Medical Oncology, Hospital Clínic Barcelona, Barcelona, Spain
8 shared publications - Carmen Loquai
Department of Dermatology, University Medical Center, Johannes-Gutenberg-University, 55122 Mainz, Germany
8 shared publications - Caroline Robert
Département de Médecine Oncologique, Gustave Roussy, Villejuif, France
8 shared publications - Claus Garbe
Centre for Dermatooncology, Department of Dermatology Eberhard Karls University Tuebingen Germany
8 shared publications - Craig B. Davis
Pfizer 2 , La Jolla, California
8 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Data from Molecular Profiling of Tisotumab Vedotin–Treated Patients Identifies Immune Pathways Associated with Clinical Activity
Purpose:Tisotumab vedotin (TV) is a tissue factor (TF)–specific antibody–drug conjugate (ADC) that was evaluated in the innovaTV 204 study in patients with recurrent or metastatic cervical cancer (r/mCC). Although TF expression is required for TV binding to tumor cells, clinical responses were found to be independent of TF levels. This study aimed to evaluate whether baseline tumor gene expression signatures consistent with the proposed mechanisms of action of TV were associated with clinical outcomes. Experimental Design:Pretreatment tumor samples from patients enrolled in innovaTV 204 (NCT03438396), a phase II, single-arm, multicenter trial of TV in r/mCC following chemotherapy, were profiled for molecular biomarkers. Gene expression analyses of immune-related signatures were stratified by clinical response. In vitro antibody-dependent cellular phagocytosis (ADCP) and antibody-dependent cellular cytotoxicity (ADCC) assays were performed using tumor cell lines with variable TF expression. Results:TF expression was confirmed in most patients but did not associate with response. Higher expression of gene signatures linked to natural killer (NK) cells and myeloid cells was associated with improved clinical outcomes. In vitro, TV induced tumor cell death through myeloid-mediated ADCP and NK-mediated ADCC across various TF expression levels. Conclusions:This work provides supportive evidence for TV mechanisms of action that involve antitumor effects through direct cytotoxic and immune effector–mediated mechanisms. The association of immune-related gene signatures with improved clinical outcomes supports a multimodal mechanism of action for TV in the clinic and provides further rationale for ADC efficacy in tumors with heterogeneous target expression.
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Molecular Profiling of Tisotumab Vedotin–Treated Patients Identifies Immune Pathways Associated with Clinical Activity
Purpose:Tisotumab vedotin (TV) is a tissue factor (TF)–specific antibody–drug conjugate (ADC) that was evaluated in the innovaTV 204 study in patients with recurrent or metastatic cervical cancer (r/mCC). Although TF expression is required for TV binding to tumor cells, clinical responses were found to be independent of TF levels. This study aimed to evaluate whether baseline tumor gene expression signatures consistent with the proposed mechanisms of action of TV were associated with clinical outcomes. Experimental Design:Pretreatment tumor samples from patients enrolled in innovaTV 204 (NCT03438396), a phase II, single-arm, multicenter trial of TV in r/mCC following chemotherapy, were profiled for molecular biomarkers. Gene expression analyses of immune-related signatures were stratified by clinical response. In vitro antibody-dependent cellular phagocytosis (ADCP) and antibody-dependent cellular cytotoxicity (ADCC) assays were performed using tumor cell lines with variable TF expression. Results:TF expression was confirmed in most patients but did not associate with response. Higher expression of gene signatures linked to natural killer (NK) cells and myeloid cells was associated with improved clinical outcomes. In vitro, TV induced tumor cell death through myeloid-mediated ADCP and NK-mediated ADCC across various TF expression levels. Conclusions:This work provides supportive evidence for TV mechanisms of action that involve antitumor effects through direct cytotoxic and immune effector–mediated mechanisms. The association of immune-related gene signatures with improved clinical outcomes supports a multimodal mechanism of action for TV in the clinic and provides further rationale for ADC efficacy in tumors with heterogeneous target expression.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (19) , 4365-4373
Molecular Profiling of Tisotumab Vedotin–Treated Patients Identifies Immune Pathways Associated with Clinical Activity
Purpose: Tisotumab vedotin (TV) is a tissue factor (TF)–specific antibody–drug conjugate (ADC) that was evaluated in the innovaTV 204 study in patients with recurrent or metastatic cervical cancer (r/mCC). Although TF expression is required for TV binding to tumor cells, clinical responses were found to be independent of TF levels. This study aimed to evaluate whether baseline tumor gene expression signatures consistent with the proposed mechanisms of action of TV were associated with clinical outcomes. Experimental Design: Pretreatment tumor samples from patients enrolled in innovaTV 204 (NCT03438396), a phase II, single-arm, multicenter trial of TV in r/mCC following chemotherapy, were profiled for molecular biomarkers. Gene expression analyses of immune-related signatures were stratified by clinical response. In vitro antibody-dependent cellular phagocytosis (ADCP) and antibody-dependent cellular cytotoxicity (ADCC) assays were performed using tumor cell lines with variable TF expression. Results: TF expression was confirmed in most patients but did not associate with response. Higher expression of gene signatures linked to natural killer (NK) cells and myeloid cells was associated with improved clinical outcomes. In vitro, TV induced tumor cell death through myeloid-mediated ADCP and NK-mediated ADCC across various TF expression levels. Conclusions: This work provides supportive evidence for TV mechanisms of action that involve antitumor effects through direct cytotoxic and immune effector–mediated mechanisms. The association of immune-related gene signatures with improved clinical outcomes supports a multimodal mechanism of action for TV in the clinic and provides further rationale for ADC efficacy in tumors with heterogeneous target expression.
- 17 July 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (19) , 4365-4373
Open AccessMolecular Profiling of Tisotumab Vedotin–Treated Patients Identifies Immune Pathways Associated with Clinical Activity
Purpose: Tisotumab vedotin (TV) is a tissue factor (TF)–specific antibody–drug conjugate (ADC) that was evaluated in the innovaTV 204 study in patients with recurrent or metastatic cervical cancer (r/mCC). Although TF expression is required for TV binding to tumor cells, clinical responses were found to be independent of TF levels. This study aimed to evaluate whether baseline tumor gene expression signatures consistent with the proposed mechanisms of action of TV were associated with clinical outcomes. Experimental Design: Pretreatment tumor samples from patients enrolled in innovaTV 204 (NCT03438396), a phase II, single-arm, multicenter trial of TV in r/mCC following chemotherapy, were profiled for molecular biomarkers. Gene expression analyses of immune-related signatures were stratified by clinical response. In vitro antibody-dependent cellular phagocytosis (ADCP) and antibody-dependent cellular cytotoxicity (ADCC) assays were performed using tumor cell lines with variable TF expression. Results: TF expression was confirmed in most patients but did not associate with response. Higher expression of gene signatures linked to natural killer (NK) cells and myeloid cells was associated with improved clinical outcomes. In vitro, TV induced tumor cell death through myeloid-mediated ADCP and NK-mediated ADCC across various TF expression levels. Conclusions: This work provides supportive evidence for TV mechanisms of action that involve antitumor effects through direct cytotoxic and immune effector–mediated mechanisms. The association of immune-related gene signatures with improved clinical outcomes supports a multimodal mechanism of action for TV in the clinic and provides further rationale for ADC efficacy in tumors with heterogeneous target expression.
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Figure 2 from Exploratory Analysis of Biomarkers and Treatment Outcomes from the COLUMBUS Study in BRAF V600E/K–Mutant Advanced or Metastatic Melanoma
PFS and OS for encorafenib plus binimetinib or encorafenib vs. vemurafenib by (A and B) ERBB2 expression level and (C and D) PI3K pathway mutation status. Bini, binimetinib; BM, biomarker; Enco, encorafenib; Vemu, vemurafenib.
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Exploratory Analysis of Biomarkers and Treatment Outcomes from the COLUMBUS Study in BRAF V600E/K–Mutant Advanced or Metastatic Melanoma
PFS and OS for encorafenib plus binimetinib or encorafenib vs. vemurafenib by (A and B) ERBB2 expression level and (C and D) PI3K pathway mutation status. Bini, binimetinib; BM, biomarker; Enco, encorafenib; Vemu, vemurafenib.
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Figure 1 from Exploratory Analysis of Biomarkers and Treatment Outcomes from the COLUMBUS Study in BRAF V600E/K–Mutant Advanced or Metastatic Melanoma
PFS and OS for encorafenib plus binimetinib or encorafenib vs. vemurafenib by (A and B) TMB and (C and D) cytolytic score. E, Volcano plots of univariable gene expression associations with OS in each arm based on z-scored gene expression values. F, Gene-set enrichment analysis of gene expression associations against hallmark gene signatures; signatures with greatest average NES across arms shown. Bini, binimetinib; BM, biomarker; CYT, cytotoxic score; Enco, encorafenib; NES, normalized enrichment scores; Vemu, vemurafenib.
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Exploratory Analysis of Biomarkers and Treatment Outcomes from the COLUMBUS Study in BRAF V600E/K–Mutant Advanced or Metastatic Melanoma
PFS and OS for encorafenib plus binimetinib or encorafenib vs. vemurafenib by (A and B) TMB and (C and D) cytolytic score. E, Volcano plots of univariable gene expression associations with OS in each arm based on z-scored gene expression values. F, Gene-set enrichment analysis of gene expression associations against hallmark gene signatures; signatures with greatest average NES across arms shown. Bini, binimetinib; BM, biomarker; CYT, cytotoxic score; Enco, encorafenib; NES, normalized enrichment scores; Vemu, vemurafenib.
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Figure 3 from Exploratory Analysis of Biomarkers and Treatment Outcomes from the COLUMBUS Study in BRAF V600E/K–Mutant Advanced or Metastatic Melanoma
Characterization of tumor samples to identify candidate molecular subtypes by K-means clustering and distribution of subtypes by biopsy site. A, Heatmap showing K-means cluster and the expression of key marker genes (AXL and MITF) and cell type scores generated by xCell. B, Distribution of K-means subgroups across biopsy sites. C, OS by K-means subgroup and treatment arm. Bini, binimetinib; Vemu, vemurafenib.
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Exploratory Analysis of Biomarkers and Treatment Outcomes from the COLUMBUS Study in BRAF V600E/K–Mutant Advanced or Metastatic Melanoma
Characterization of tumor samples to identify candidate molecular subtypes by K-means clustering and distribution of subtypes by biopsy site. A, Heatmap showing K-means cluster and the expression of key marker genes (AXL and MITF) and cell type scores generated by xCell. B, Distribution of K-means subgroups across biopsy sites. C, OS by K-means subgroup and treatment arm. Bini, binimetinib; Vemu, vemurafenib.
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Table 1 from Exploratory Analysis of Biomarkers and Treatment Outcomes from the COLUMBUS Study in BRAF V600E/K–Mutant Advanced or Metastatic Melanoma
Baseline patient characteristics by biomarker status.
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Exploratory Analysis of Biomarkers and Treatment Outcomes from the COLUMBUS Study in BRAF V600E/K–Mutant Advanced or Metastatic Melanoma
Baseline patient characteristics by biomarker status.
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Figure 4 from Exploratory Analysis of Biomarkers and Treatment Outcomes from the COLUMBUS Study in BRAF V600E/K–Mutant Advanced or Metastatic Melanoma
PFS and OS by detection of BRAF V600 alterations in ctDNA at (A and B) baseline and (C and D) on treatment. Only patients with BRAF V600 alteration detections at baseline are shown in C and D. Bini, binimetinib; D, detectable; Enco, encorafenib; ND, nondetectable; Vemu, vemurafenib.
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Exploratory Analysis of Biomarkers and Treatment Outcomes from the COLUMBUS Study in BRAF V600E/K–Mutant Advanced or Metastatic Melanoma
PFS and OS by detection of BRAF V600 alterations in ctDNA at (A and B) baseline and (C and D) on treatment. Only patients with BRAF V600 alteration detections at baseline are shown in C and D. Bini, binimetinib; D, detectable; Enco, encorafenib; ND, nondetectable; Vemu, vemurafenib.